Klin Farmakol Farm. 2010;24(3):127-134

Anti-angiogenic drugs in clinical practice

Tomáš Svoboda

KOC FN Plzeň

Because of the need of neoangiogenesis provided by the VEGF-receptors family they seem to be one of the key target structrures. Their

activation is envolved in the tumor growth proces and development of metastases. The effort to protect prior this undesirable influence

started by unblocked angiogenesis is a logical step in a majority diseases in oncology. Anti-VEGF and other structures targeted

drugs with a similar mode of action become a standard part of anticancer therapy already in monotherapy as far as in combination with

chemotherapy or radiation. The greatest amount of data available we do have with bevacizumab; however, sunitinib and sorafenib also

found their place and the spectrum of substances associated with antiangiogenic effect is broad enough. I tried to focus this problematic

closely but more in a general aspect with respect to the last results in this overview.

Keywords: antiangiogenesis, VEGF, bevacizumab, sunitinib, sorafenib, everolimus

Published: October 15, 2010  Show citation